Integer Holdings Co. (NYSE:ITGR) Receives Average Recommendation of “Moderate Buy” from Analysts

Integer Holdings Co. (NYSE:ITGR) has earned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $133.86.

A number of research analysts have weighed in on ITGR shares. Citigroup boosted their target price on shares of Integer from $118.00 to $124.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 22nd. Benchmark reissued a “buy” rating and set a $130.00 price objective on shares of Integer in a research report on Friday, August 2nd. Finally, Oppenheimer assumed coverage on Integer in a report on Tuesday, July 16th. They issued an “outperform” rating and a $135.00 target price on the stock.

Insider Activity at Integer

In related news, Director Jean M. Hobby sold 11,960 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $119.66, for a total value of $1,431,133.60. Following the completion of the transaction, the director now directly owns 2,280 shares in the company, valued at $272,824.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.00% of the company’s stock.

Institutional Trading of Integer

Several institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its position in shares of Integer by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 382,936 shares of the medical equipment provider’s stock worth $37,941,000 after buying an additional 3,504 shares during the period. Principal Securities Inc. acquired a new stake in shares of Integer in the 4th quarter valued at $67,000. Quadrant Capital Group LLC boosted its stake in shares of Integer by 10.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,427 shares of the medical equipment provider’s stock valued at $141,000 after purchasing an additional 132 shares in the last quarter. Great Lakes Advisors LLC bought a new stake in shares of Integer in the 4th quarter worth about $2,684,000. Finally, Norges Bank acquired a new stake in shares of Integer during the 4th quarter worth about $18,697,000. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Price Performance

NYSE ITGR opened at $126.21 on Wednesday. Integer has a fifty-two week low of $69.40 and a fifty-two week high of $131.17. The stock’s 50-day moving average is $122.24 and its two-hundred day moving average is $118.32. The firm has a market cap of $4.23 billion, a P/E ratio of 43.67, a price-to-earnings-growth ratio of 1.81 and a beta of 1.09. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.29 and a quick ratio of 1.96.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.06. The business had revenue of $436.20 million for the quarter, compared to the consensus estimate of $437.00 million. Integer had a return on equity of 11.48% and a net margin of 6.31%. The firm’s revenue was up 9.0% compared to the same quarter last year. During the same period last year, the business earned $1.14 EPS. On average, analysts anticipate that Integer will post 5.31 earnings per share for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.